亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药

已收盘 11-06 16:08:52

29.280

-0.960

-3.17%

最高30.500	最低28.840	成交量186.06万
今开28.840	昨收30.240	日振幅5.49%
总市值109.80亿	流通市值109.80亿	总股本3.75亿
成交额5,495万	换手率0.50%	流通股本3.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药","latestPrice":29.28,"timestamp":1793952532006,"preClose":30.24,"halted":0,"volume":1860600,"delay":0,"changeRate":-0.03174603174603166,"floatShares":375000000,"shares":375000000,"eps":-4.101254683115703,"marketStatus":"已收盘","change":-0.96,"latestTime":"11-06 16:08:52","open":28.84,"high":30.5,"low":28.84,"amount":54949986,"amplitude":0.054894,"askPrice":29.28,"askSize":2100,"bidPrice":29.26,"bidSize":3400,"shortable":3,"etf":0,"ttmEps":-4.641795349771919,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":30.24,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.701799,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"1132698903","title":"亚盛医药10月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1132698903","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132698903?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:36","pubTimestamp":1793889369,"startTime":"0","endTime":"0","summary":"亚盛医药于2026年11月5日发布了截至2026年10月31日的股份变动月报表。报告显示，公司注册股本为500,000,000股，面值每股USD 0.0001，总注册股本USD 50,000，与上月保持一致。公司已发行股本方面，截至10月31日，已发行及流通在外的普通股总数为374,962,086股，与上月底相同，当月并未发生新增发行、回购或注销等股份变动。公司声明目前公共持股比例符合适用的香港联交所上市规则要求。本月内并无因行使期权而新增发行股份或获得行使期权的资金。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681236018","title":"港股异动 | 亚盛医药(06855.HK)涨超5% 多项临床进展将在ASH年会展示 APG-5918首次公布即获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2681236018","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681236018?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:44","pubTimestamp":1793843053,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681680094","title":"亚盛医药：多项临床进展将在2026年ASH年会展示 APG-5918获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2681680094","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681680094?lang=zh_cn&edition=full","pubTime":"2026-11-05 07:17","pubTimestamp":1793834220,"startTime":"0","endTime":"0","summary":"南财智讯11月5日电，亚盛医药（06855.HK）发布自愿公告，公司多项临床和临床前研究进展入选第68届美国血液学会(ASH)年会，涉及奥雷巴替尼、利沙托克拉、APG-5918和APG-3288四个品种。其中，APG-5918首次公布临床数据即获口头报告，将展示其用于治疗复发/难治T细胞淋巴瘤的疗效与安全性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611053922414721.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611053922414721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06855","AAPG","APG","BK4139","BK1574","BK4129","LU1923622291.USD","LU2125909759.SGD","LU2125909916.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115285650","title":"亚盛医药（06855）四大创新管线亮相2026 ASH年会　APG-5918首秀即获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1115285650","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115285650?lang=zh_cn&edition=full","pubTime":"2026-11-05 06:55","pubTimestamp":1793832940,"startTime":"0","endTime":"0","summary":"2026年11月5日，亚盛医药集团发布自愿公告称，公司旗下四大创新抗肿瘤产品——第三代 BCR-ABL 抑制剂奥雷巴替尼、国产原创 Bcl-2 抑制剂利沙托克拉、PRC2/EED 抑制剂 APG-5918 及 BTK 降解剂 APG-3288——共计八项临床及临床前研究成果入选将于2026年12月12日至12月15日在美国路易斯安那州新奥尔良举行的第68届美国血液学会年会，并涵盖口头报告、墙报及在线发表三种形式。其中国内首创 EED 抑制剂 APG-5918首次披露临床数据即获口头报告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678434786","title":"亚盛医药盘中涨超5%，ESMO年会中国创新药数据集中发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2678434786","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678434786?lang=zh_cn&edition=full","pubTime":"2026-10-28 13:14","pubTimestamp":1793164440,"startTime":"0","endTime":"0","summary":"10月28日，亚盛医药(06855.HK)盘中涨超5%，截至13时9分，涨5.23%，报29.36港元/股，成交额3153.94万港元。消息面上，2026年欧洲肿瘤内科学会年会召开，29项中国创新药研究入选突破性摘要， ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261028/c681180210.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261028/c681180210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["06855","BK1161","BK4139","BK1574","AAPG","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强，截至发稿，恒瑞医药 涨11.14%，金斯瑞生物涨9.39%，康方生物涨4.70%，诺诚健华涨3.50%，欧康维视生物-B涨3.33%，亚盛医药涨2.65%，翰森制药涨2.32%。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","LU1961090484.USD","600276","LU1820825898.SGD","LU2778985437.USD","BK0183","06855","BK0196","BK1576","KURE","BK1161","LNGR","BK1589","LU1720050803.USD","HK0000320264.USD","159992","BK1583","BK0188","IBBQ","09926","LU0348783233.USD","LU0417516571.SGD","LU1997245177.USD","LU0417516902.SGD","KCE","LU0348827113.USD","06978","LU0634319403.HKD","IE00B543WZ88.USD","LU1064130708.USD","LU1655091616.SGD","LU0348735423.USD","01276","LU2328871848.SGD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU2097828474.EUR","01477","LU2289578879.USD","09969","03692","LU1328615791.USD","LU0405327148.USD","LU0359201612.USD","LU2476274720.SGD","01548","BK1191","LU1781817850.SGD","MEDX","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146578497","title":"亚盛医药(06855)受托人10月27日购入20万股 用于2022年RSU计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1146578497","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146578497?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:45","pubTimestamp":1793105134,"startTime":"0","endTime":"0","summary":"10月29日，亚盛医药集团公告披露，其受托人已于2026年10月27日透过联交所场内购入公司现有股份20万股，用于履行2022年受限制股份单位计划的归属。公司表示，受托人所持股份均按照2022年受限制股份单位计划规则及双方签订的信托契据管理，受托人不得行使所持股份的表决权。此前，公司已就该RSU计划于2022年6月23日首次授出奖励，并在后续若干时间点进一步授出奖励。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678177097","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678177097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678177097?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:43","pubTimestamp":1793104986,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年10月27日，受托人就2022年受限制股份单位计划目的于场内购买合共 20万股现有股份(所购买股份)以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","06855","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678140953","title":"医药股走低 恒生生物科技指数跌2.48% 映恩生物-B（09606）大跌31.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678140953","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678140953?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:18","pubTimestamp":1793081937,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股走低，恒生生物科技指数大幅跌2.48%。成分股中，映恩生物-B跌31.05%，亚盛医药跌6.70%，科伦博泰生物跌5.96%，三生制药跌5.10%，石药集团跌4.25%，康方生物跌3.63%，中国生物制药跌3.26%，翰森制药跌3.10%，百济神州跌3.03%。近两个月连锁药房密集推出股权激励，驱动板块逻辑从“政策博弈”转向“业绩锚定”。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994559","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","09939","BK1583","LU0501845795.SGD","LU0140636845.USD","LU0314109678.HKD","LU0348784397.USD","LU0880133367.SGD","LU0348783233.USD","IE00B5MMRT66.SGD","LU1226288253.USD","LU0348827113.USD","06855","LU0634319403.HKD","LU1961090484.USD","HK0000252152.HKD","LU0588546209.SGD","LU1226287792.SGD","03692","LU1226287529.USD","09606","LU0561508036.HKD","LU1226287875.USD","LU1328277881.USD","09926","01177","IE00B543WZ88.USD","06160","LU1969619763.USD","KURE","HK0000500386.USD","IE00BZ08YR35.GBP","01093","159938","06990","LU0417516902.SGD","LU1719994722.HKD","BK1515","LU2039709279.SGD","01530","LU2488822045.USD","IE0008369823.USD","LU2476274720.SGD","LU0348766576.USD","LU0417516738.SGD","BK1588","SG9999004220.SGD","LU0315179316.USD","IE0008368742.USD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677891737","title":"亚盛医药盘中涨超5%，新药获突破性治疗认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2677891737","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677891737?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:05","pubTimestamp":1792731900,"startTime":"0","endTime":"0","summary":"10月23日，亚盛医药(06855.HK)盘中涨超5%，截至13时3分，涨5.26%，报30.00港元/股，成交额5190.61万港元。消息面上，公司原创1类新药Bcl-2抑制剂利生妥获国家药监局药审中心纳入突破性治疗 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261023/c681016511.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261023/c681016511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["06855","AAPG","BK1161","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181820035","title":"亚盛医药（06855）受托人斥资574.06万元港币回购20万股执行2022年限制性股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1181820035","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181820035?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:50","pubTimestamp":1792673446,"startTime":"0","endTime":"0","summary":"2026年10月22日，亚盛医药集团发布自愿公告称，其受托人已于同日通过联交所场内购入公司现有股份200,000股，用于履行2022年限制性股份单位计划的归属需求。公告披露，此次购股总对价为5,740,622港元，平均每股代价约28.70港元，不含相关开支及税项。公司同时重申，除此前公告披露的授出事宜外，现阶段未作额外授出。董事会由主席兼执行董事杨大俊博士授权发布本次公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677630979","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买20万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2677630979","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677630979?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:49","pubTimestamp":1792673398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)公布，于2026年10月22日，受托人就2022年受限制股份单位计划目的于场内购买合共20万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","AAPG","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677986646","title":"港股异动 | 亚盛医药(06855)早盘涨超4% 利生妥获药审中心突破性治疗品种认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2677986646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677986646?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:33","pubTimestamp":1792550031,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药早盘涨超4%。消息面上，亚盛医药公告，公司原创1类新药Bcl-2抑制剂利生妥获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合阿可替尼治疗成人初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK4588","BK1161","BK4585","BK4139","VXUS","KCAI","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677964698","title":"港股异动 | 亚盛医药(06855.HK)早盘涨超4% 利生妥获药审中心突破性治疗品种认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2677964698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677964698?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:33","pubTimestamp":1792550031,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677361220","title":"亚盛医药(06855.HK)利生妥®治疗初治慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤(CLL/SLL)获突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2677361220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677361220?lang=zh_cn&edition=full","pubTime":"2026-10-21 07:04","pubTimestamp":1792537498,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","LU1188198961.HKD","06855","02228","BK1521","02269","02157","LU1242518931.SGD","06978","01276","LU1152091754.HKD","LU0359201885.HKD","IE0008369823.USD","09969","BK1576","02162","159992","LU0211977185.USD","02268","01093","LU0588546209.SGD","KURE","LU0043850808.USD","LU0128522744.USD","LU2543165471.USD","01952","06990","LU1993786604.SGD","03692","BK1610","00013","LU0979878070.USD","LU0196878994.USD","MEDX","01177","BK1589","LNGR","LU2488822045.USD","LU0072913022.USD","LU0348827113.USD","LU1008478684.HKD","LU1720050803.USD","LU0052750758.USD","BK1161","LU2476274720.SGD","LU1794554557.SGD","LU0417516738.SGD","LU1226288170.HKD","IBBQ","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675587305","title":"亚盛医药：受托人购入20万股 金额578万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675587305","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675587305?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:46","pubTimestamp":1792068360,"startTime":"0","endTime":"0","summary":"亚盛医药（06855）发布公告，受托人于10月15日根据2022年受限制股份单位计划目的，购买了合共20万股现有股份，占公告日期已发行股份总数的约0.05%，所购股份的总代价为578万港元，每股平均代价约为28.89港元（不包括所有相关开支、交易缴费、佣金、税项、税费及税款）。截至公告日，受托人根据该计划已在场内购买了总计292万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610153897136140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610153897136140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06855","BK1574","AAPG","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582151","title":"亚盛医药(06855.HK)：受托人就2022年受限制股份单位计划目的购买20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582151?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:35","pubTimestamp":1792067735,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06855","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142075306","title":"亚盛医药斥资约577.89万元回购20万股 用于2022年受限制股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1142075306","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142075306?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:35","pubTimestamp":1792067726,"startTime":"0","endTime":"0","summary":"10月15日，亚盛医药公告称，其受托人已于同日通过场内交易方式购入公司现有股份20.00万股，占公告日已发行股份总数的约0.05%，用于履行公司2022年受限制股份单位计划的归属需求。上述股份均按照RSU计划及信托契据条款持有，受托人不得行使所持股份的表决权。亚盛医药表示，本次股份购回旨在确保公司能够按时向符合条件的参与者交付股份，兑现既定激励承诺。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674828354","title":"亚盛医药盘中涨超5%，高管认购及受托人购股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674828354","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674828354?lang=zh_cn&edition=full","pubTime":"2026-10-12 10:22","pubTimestamp":1791771720,"startTime":"0","endTime":"0","summary":"10月12日，亚盛医药(06855.HK)盘中涨超5%，截至10时20分，涨5.24%，报29.70港元/股，成交额2228.02万港元。消息面上，9月28日，亚盛医药发布公告，于2026年9月28日，受托人就2022年受限制股 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261012/c680574977.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261012/c680574977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["06855","BK1161","BK4139","BK1574","AAPG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.0716},{"period":"1month","weight":-0.0175},{"period":"3month","weight":-0.1701},{"period":"6month","weight":-0.2908},{"period":"1year","weight":-0.5387},{"period":"ytd","weight":-0.4212}],"compareEarnings":[{"period":"1week","weight":0.0801},{"period":"1month","weight":0.0213},{"period":"3month","weight":-0.0339},{"period":"6month","weight":-0.0605},{"period":"1year","weight":-0.0439},{"period":"ytd","weight":-0.0325}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.714286,"avgChangeRate":0.098263},{"month":5,"riseRate":0.428571,"avgChangeRate":0.029409},{"month":6,"riseRate":0.714286,"avgChangeRate":0.240354},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.06344},{"month":8,"riseRate":0.714286,"avgChangeRate":0.0422},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.08283},{"month":10,"riseRate":0.428571,"avgChangeRate":0.017677},{"month":11,"riseRate":0.5,"avgChangeRate":0.067978},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药","nameEN":"ASCENTAGE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,06855,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}